Search Tag: Cardiff Oncology

Executive Health Management

2022 12 Apr

Cardiff Oncology, Inc., a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers has announced that  Katherine L. Ruffner , M.D., chief medical officer (CMO), will be leaving the Company on  April 22, 2022 , to pursue a new opportunity. Dr. Ruffner will provide Cardiff Oncology with transitional...Read more